Alzheimers is a very big marke

10
4
Favorite

nnavinraj
2021-06-08

Alzheimers is a very big market. Let's hope this one succeeds. Please like and reply.

Biogen’s Japanese Partner Has a Second Alzheimer’s Drug Coming

Biogen Inc. beat the odds, bringing the first drug intended to slow the progression of Alzheimer’s d

Biogen’s Japanese Partner Has a Second Alzheimer’s Drug Coming

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（4）

Top
Latest

hitithard
·2021-06-08
Comment on my comment
Reply
Like
Report
Fold Replies
- michiec:
  Ok please comment mine too
  2021-06-08
  Reply
  Report
BrianLTS
·2021-06-12
Can’t agree more.
Reply
Like
Report
50160107Acct
·2021-06-14
K
Reply
Like
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":117698459,"tweetId":"117698459","gmtCreate":1623135254771,"gmtModify":1704196791022,"author":{"id":3578099872805879,"idStr":"3578099872805879","authorId":3578099872805879,"authorIdStr":"3578099872805879","name":"nnavinraj","avatar":"https://static.tigerbbs.com/ff06b63457b059098678fc929e99957c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.32%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Alzheimers is a very big market. Let's hope this one succeeds. Please like and reply.&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Alzheimers is a very big market. Let's hope this one succeeds. Please like and reply.&nbsp;</p></body></html>","text":"Alzheimers is a very big market. Let's hope this one succeeds. Please like and reply.","highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/117698459","repostId":1135714831,"repostType":4,"repost":{"id":"1135714831","kind":"news","pubTimestamp":1623135005,"share":"https://www.laohu8.com/m/news/1135714831?lang=&edition=full","pubTime":"2021-06-08 14:50","market":"us","language":"en","title":"Biogen’s Japanese Partner Has a Second Alzheimer’s Drug Coming","url":"https://stock-news.laohu8.com/highlight/detail?id=1135714831","media":"bloomberg","summary":"Biogen Inc. beat the odds, bringing the first drug intended to slow the progression of Alzheimer’s d","content":"<p>Biogen Inc. beat the odds, bringing the first drug intended to slow the progression of Alzheimer’s disease to the U.S market. Investors are hoping Eisai Co. Ltd, its Japanese partner in the medicine, can do it again with a second compound from the pair that’s still in development.</p><p>The U.S. Food and Drug Administration’s backing of the drug Aduhelm may boost the chances for BAN2401 and Tokyo-based Eisai, which is in a sales and profit sharing agreement with Biogen for both treatments. The drugs work by targeting the beta amyloid protein that clogs the brains of patients with Alzheimer’s disease.</p><p>Researchers long believed that interfering with the protein, a hallmark of the disease, was the key to treating the condition, but pharmaceutical companies spent billions of dollars on experimental compounds that failed again and again to slow the inexorable progression of the mind-wasting disease. Aduhelm is the first such medicine to make it to the market.</p><p>“This approval will have a halo effect on BAN2401 and the wider pipeline,” said Jefferies analyst Stephen Barker. “It will certainly impact how the stock market evaluates the Alzheimer’s research from Biogen and Eisai in general.”</p><p>The Japanese drugmaker partnered with Biogenin 2014to co-develop several Alzheimer’s related compounds. In 2017, Eisai exercised an option toexpand the agreement</p><p>Eisai’s shares were untraded in Tokyo Tuesday amid a trading imbalance, as bids outweighed offers. Biogen shares closed at $395.85, up 38.3% in U.S. trading.</p><p>Two Trials</p><p>Eisai is leading two pivotal trials on BAN2401, which also goes by the name lecanemab. Final results for the study in patients with early-stage disease are expected within the next year. The FDA’s approval of Aduhelm may indicate a shift in how the agency thinks about Alzheimer’s disease, and the sentiments are lifting expectations for the experimental compound’s future.</p><p>“Our other drug lecanemab is also based on the beta amyloid hypothesis, so we are very encouraged by this approval,” an Eisai spokesman told Bloomberg by phone.</p><p>Closer on the calendar are regulatory approval decisions for Aduhelm in Europe and Japan, which will likely come later this year, Barker said.</p><p>Japan’s top government spokesman Katsunobu Kato said Tuesday that the country would review the drug in an appropriate manner, while Australia’s Therapeutic Goods Administration said it is currently evaluating the medication.</p><p>For the Aduhelm agreement, Eisai will book sales in Asia outside of China and South Korea, while Biogen will book most of the rest of the world, including U.S. and Europe.</p><p>Profits will be split about 50-50, with Biogen taking a greater share in U.S. and Europe, and Eisai taking a greater share in Japan and Asia, other than China and South Korea.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen’s Japanese Partner Has a Second Alzheimer’s Drug Coming</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen’s Japanese Partner Has a Second Alzheimer’s Drug Coming\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 14:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-08/biogen-s-alzheimer-drug-nod-may-bode-well-for-eisai-s-efforts><strong>bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc. beat the odds, bringing the first drug intended to slow the progression of Alzheimer’s disease to the U.S market. Investors are hoping Eisai Co. Ltd, its Japanese partner in the medicine, ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-08/biogen-s-alzheimer-drug-nod-may-bode-well-for-eisai-s-efforts\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-08/biogen-s-alzheimer-drug-nod-may-bode-well-for-eisai-s-efforts","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135714831","content_text":"Biogen Inc. beat the odds, bringing the first drug intended to slow the progression of Alzheimer’s disease to the U.S market. Investors are hoping Eisai Co. Ltd, its Japanese partner in the medicine, can do it again with a second compound from the pair that’s still in development.The U.S. Food and Drug Administration’s backing of the drug Aduhelm may boost the chances for BAN2401 and Tokyo-based Eisai, which is in a sales and profit sharing agreement with Biogen for both treatments. The drugs work by targeting the beta amyloid protein that clogs the brains of patients with Alzheimer’s disease.Researchers long believed that interfering with the protein, a hallmark of the disease, was the key to treating the condition, but pharmaceutical companies spent billions of dollars on experimental compounds that failed again and again to slow the inexorable progression of the mind-wasting disease. Aduhelm is the first such medicine to make it to the market.“This approval will have a halo effect on BAN2401 and the wider pipeline,” said Jefferies analyst Stephen Barker. “It will certainly impact how the stock market evaluates the Alzheimer’s research from Biogen and Eisai in general.”The Japanese drugmaker partnered with Biogenin 2014to co-develop several Alzheimer’s related compounds. In 2017, Eisai exercised an option toexpand the agreementEisai’s shares were untraded in Tokyo Tuesday amid a trading imbalance, as bids outweighed offers. Biogen shares closed at $395.85, up 38.3% in U.S. trading.Two TrialsEisai is leading two pivotal trials on BAN2401, which also goes by the name lecanemab. Final results for the study in patients with early-stage disease are expected within the next year. The FDA’s approval of Aduhelm may indicate a shift in how the agency thinks about Alzheimer’s disease, and the sentiments are lifting expectations for the experimental compound’s future.“Our other drug lecanemab is also based on the beta amyloid hypothesis, so we are very encouraged by this approval,” an Eisai spokesman told Bloomberg by phone.Closer on the calendar are regulatory approval decisions for Aduhelm in Europe and Japan, which will likely come later this year, Barker said.Japan’s top government spokesman Katsunobu Kato said Tuesday that the country would review the drug in an appropriate manner, while Australia’s Therapeutic Goods Administration said it is currently evaluating the medication.For the Aduhelm agreement, Eisai will book sales in Asia outside of China and South Korea, while Biogen will book most of the rest of the world, including U.S. and Europe.Profits will be split about 50-50, with Biogen taking a greater share in U.S. and Europe, and Eisai taking a greater share in Japan and Asia, other than China and South Korea.","news_type":1},"isVote":1,"tweetType":1,"viewCount":840,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["MKFG","AONE.U"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":71,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":4629965,"commentId":"4629965","gmtCreate":1623135461998,"gmtModify":1663228187345,"authorId":3570063321997588,"author":{"id":3570063321997588,"idStr":"3570063321997588","authorId":3570063321997588,"name":"hitithard","avatar":"https://static.tigerbbs.com/309ce7b357018aa7b946332c2fe8725c","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.91%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":117698459,"objectIdStr":"117698459","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Comment on my comment","text":"Comment on my comment","html":"Comment on my comment","likeSize":0,"commentSize":1,"subComments":[{"id":4629978,"commentId":"4629978","gmtCreate":1623135591326,"gmtModify":1663228187247,"authorId":3576840215575990,"author":{"id":3576840215575990,"idStr":"3576840215575990","authorId":3576840215575990,"name":"michiec","avatar":"https://static.tigerbbs.com/a4ab42a03acfbe58db7e84b49daf9682","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":117698459,"objectIdStr":"117698459","type":1,"supId":4629965,"supIdStr":"4629965","prevId":0,"prevIdStr":"0","content":"Ok please comment mine too","text":"Ok please comment mine too","html":"Ok please comment mine too"}],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":4705198,"commentId":"4705198","gmtCreate":1623472131040,"gmtModify":1635325973168,"authorId":3572236737712328,"author":{"id":3572236737712328,"idStr":"3572236737712328","authorId":3572236737712328,"name":"BrianLTS","avatar":"https://static.tigerbbs.com/ec1e776b8113215c077b67791e4f544c","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.14","exceedPercentage":"93.77%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":117698459,"objectIdStr":"117698459","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Can’t agree more.","text":"Can’t agree more.","html":"Can’t agree more.","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":4738966,"commentId":"4738966","gmtCreate":1623636287491,"gmtModify":1663228705773,"authorId":3582706615498692,"author":{"id":3582706615498692,"idStr":"3582706615498692","authorId":3582706615498692,"name":"50160107Acct","avatar":"https://static.tigerbbs.com/6be9d18c4a63434e372aa39f7de3ec12","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":117698459,"objectIdStr":"117698459","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"K","text":"K","html":"K","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}